3 Finished Dosage Generics Maker, Oleochemical Additives Leader and Artificial Leather Maker Stocks With a Strong Future Roadmap: Strides Pharma Science, Fine Organic Industries and Mayur Uniquoters

Generics, additive and artificial leather stocks offer a focused view of a sector where demand keeps widening. Strides Pharma Science, Fine Organic Industries and Mayur Uniquoters cover a finished dosage generics maker, an oleochemical additives leader and an artificial leather maker.

This list covers three generics, additive and artificial leather stocks with complete current figures: Strides Pharma Science, Fine Organic Industries and Mayur Uniquoters. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generics, Additive and Artificial Leather Stocks?

Generics, additive and artificial leather stocks are listed companies that make finished dosage generics for regulated markets, produce food and plastics additives from natural oils, and manufacture artificial leather used in footwear and car interiors. Their earnings depend on export orders and customer industries.

Generics, Additive and Artificial Leather Stocks at a Glance

On valuation, Strides Pharma Science and Mayur Uniquoters trade at a P/E below the industry P/E, while Fine Organic Industries trades above it, which reflects the growth the market already expects. Readers comparing generics, additive and artificial leather stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generics, additive and artificial leather stocks can use the coming numbers to test whether growth is holding.

Why Do Generics, Additive and Artificial Leather Stocks Have a Strong Roadmap in India?

Generics, additive and artificial leather stocks have a strong roadmap in India because growing demand for generics, wider use of specialty additives and rising demand for synthetic leather keep widening the market for these export linked companies.

• Generics. Regulated markets need affordable medicines.
• Additives. Food, plastics and coatings use specialty inputs.
• Synthetic leather. Footwear and car makers use artificial leather.

Why Strides Pharma Science Features Among These Generics, Additive and Artificial Leather Stocks

Among the generics, additive and artificial leather stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Why Fine Organic Industries Features Among These Generics, Additive and Artificial Leather Stocks

Among the drug and additive export shares on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.

Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%.

In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1.

Roadmap: The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.

What to watch: Monitor raw material prices, export demand and the pace of new capacity addition.

Why Mayur Uniquoters Features Among These Generics, Additive and Artificial Leather Stocks

Among the three companies on this list, Mayur Uniquoters is a Rajasthan-based maker of artificial leather and synthetic fabrics used in footwear, automotive upholstery, furniture and other applications.

In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%.

Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P/E of 15.7, below the industry P/E of 37.9.

Roadmap: The company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.

What to watch: Check the volume trend in automotive and footwear customers and export sales.

Strides Pharma Science vs Fine Organic Industries vs Mayur Uniquoters on Key Financials

The table below sets the three generics, additive and artificial leather stocks side by side on revenue, profit and margin, using reported figures.

Strides Pharma Science posts the highest return on equity in this group at 17.9%. Strides Pharma Science combines the largest FY26 revenue at Rs 5,009 crore with the fastest revenue growth, a 11.8% compound annual rate. A useful habit with generics, additive and artificial leather stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several formulation and additive stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Generics, Additive and Artificial Leather Stocks

Every theme carries risks that deserve a check before any decision. For these generics, additive and artificial leather stocks, the main points are: Long-term drug and additive export shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Pricing pressure. Generic prices can change by market.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter generics, additive and artificial leather stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Generics, Additive and Artificial Leather Stocks

Generics, additive and artificial leather stocks reward patient research into demand, execution and financial strength. Strides Pharma Science, Fine Organic Industries and Mayur Uniquoters each have a clear plan to grow. Based on the 3 November 2026 close, Strides Pharma Science trades at Rs 1,037.3, Fine Organic Industries at Rs 5,089 and Mayur Uniquoters at Rs 753.55. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these generics, additive and artificial leather stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track generics, additive and artificial leather stocks, set price alerts and get research-backed stock ideas.

What are generics, additive and artificial leather stocks?

Ans. Generics, additive and artificial leather stocks are listed companies that make finished dosage generics for regulated markets, produce food and plastics additives from natural oils, and manufacture artificial leather used in footwear and car interiors. Their earnings depend on export orders and customer industries. This list looks at three of them, Strides Pharma Science, Fine Organic Industries and Mayur Uniquoters, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.

Which generics, additive and artificial leather stocks are covered in this list?

Ans. This list covers Strides Pharma Science, Fine Organic Industries and Mayur Uniquoters. Based on the 3 November 2026 close, Strides Pharma Science traded at Rs 1,037.3, Fine Organic Industries at Rs 5,089 and Mayur Uniquoters at Rs 753.55. Their return on equity ranges from 15.7% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 11.8%.

Why do generics, additive and artificial leather stocks have a strong future roadmap in India?

Ans. Generics, additive and artificial leather stocks have a strong roadmap in India because growing demand for generics, wider use of specialty additives and rising demand for synthetic leather keep widening the market for these export linked companies. The main drivers are as follows. Generics. Regulated markets need affordable medicines. Additives. Food, plastics and coatings use specialty inputs. Synthetic leather. Footwear and car makers use artificial leather. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

How has Fine Organic Industries performed financially?

Ans. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.

How has Mayur Uniquoters performed financially?

Ans. Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P/E of 15.7, below the industry P/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.

What risks should investors check before buying generics, additive and artificial leather stocks?

Ans. Investors should check a few risks before buying generics, additive and artificial leather stocks. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of generics, additive and artificial leather stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.